Jpmorgan Chase & CO Cybin Inc. Transaction History

Jpmorgan Chase & CO

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$0.26 - $0.46 $189 - $335	-729 Reduced 70.5%	305 $0
Q4 2023 Dec 26, 2024	BUY	$0.38 - $0.65 $392 - $672	1,034 New	1,034 $0
Q4 2023 Feb 12, 2024	BUY	$0.38 - $0.65 $277 - $473	729 Added 239.02%	1,034 $0
Q3 2023 Nov 14, 2023	BUY	$0.29 - $0.63 $88 - $192	305 New	305 $0
Q4 2022 Feb 13, 2023	BUY	$0.26 - $0.64 $520 - $1,280	2,000 Added 12.5%	18,000 $5,000
Q3 2022 Nov 14, 2022	BUY	$0.48 - $1.11 $7,533 - $17,421	15,695 Added 5145.9%	16,000 $48,000
Q2 2022 Aug 11, 2022	BUY	$0.41 - $0.88 $125 - $268	305 New	305 $1,000

66.1K

Ticker CYBN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 166,120,000
Market Cap $1.58B
Description
Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to t...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.